drugset / Trial / NCT01868685

Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients

NCT01868685

Phase 2 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to evaluate the effect of BYM338 on muscle mass and function in Group III failure to wean patients, as compared to placebo controls.

Timeline

Start
2014-04
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimagrumab Monoclonal antibody

Indications

No indication recorded.